Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2393e079c31c6f8

Jump to content

KEAP1

From Wikipedia, the free encyclopedia

KEAP1
Identifiers
AliasesKEAP1, INrf2, KLHL19, kelch like ECH associated protein 1
External IDsOMIM: 606016; MGI: 1858732; HomoloGene: 8184; GeneCards: KEAP1; OMA:KEAP1 - orthologs
Available structures
PDBOrtholog search: PDBe RCSB
Orthologs
SpeciesHumanMouse
Entrez

9817

50868

Ensembl

ENSG00000079999

ENSMUSG00000003308

UniProt

Q14145

Q9Z2X8

RefSeq (mRNA)

NM_012289
NM_203500

NM_001110305
NM_001110306
NM_001110307
NM_016679

RefSeq (protein)

NP_036421
NP_987096

NP_001103775
NP_001103776
NP_001103777
NP_057888

Location (UCSC)Chr 19: 10.49 – 10.5 MbChr 9: 21.14 – 21.15 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Kelch-like ECH-associated protein 1 is an E3 ubiquitin ligase that in humans is encoded by the Keap1 gene.[5]

Structure

[edit]

Keap1 has four discrete protein domains. The N-terminal Broad complex, Tramtrack and Bric-à-Brac (BTB) domain contains the Cys151 residue, which is one of the important cysteines in stress sensing. The intervening region (IVR) domain contains two critical cysteine residues, Cys273 and Cys288, which are a second group of cysteines important for stress sensing. A double glycine repeat (DGR) and C-terminal region domains collaborate to form a β-propeller structure, which is where Keap1 interacts with Nrf2.

Function

[edit]

Keap1 functions as a negative regulator of Nrf2, a master regulator of the cellular antioxidant response that contributes to protection against oxidative stress.[6][7][8]

Under quiescent conditions, Nrf2 is retained in the cytoplasm through association with Keap1, which promotes ubiquitination and subsequent proteolysis of Nrf2. This sequestration and degradation mechanism mediates repression of Nrf2-dependent transcriptional activity.

Keap1 has been characterized as both a tumor suppressor gene and a metastasis suppressor gene.[9]

Interactions

[edit]
The KEAP1/NRF2 pathway modulates the body's antitumor response

Keap1 has been shown to interact with Nrf2.[6][7][8]

Several studies have identified an autoregulatory circuit linking KEAP1 and NRF2 expression. In mouse Keap1 (INrf2), Lee and colleagues identified an antioxidant response element (ARE) located on the negative strand that links Nrf2 activation to Keap1 transcription.[10]

Analysis of NRF2 occupancy in human lymphocytes identified an approximately 700 bp region within the KEAP1 promoter as highly enriched for NRF2 binding.[11]

These findings support reciprocal regulation between NRF2 and KEAP1. NRF2-driven KEAP1 expression has subsequently been characterized in human cancers, particularly squamous cell cancers, providing additional insight into regulation of NRF2 signaling.[12]

Clinical significance

[edit]

Mutations

[edit]

Mutations in KEAP1 that result in loss-of-function are not linked to familial cancers, though they do predispose individuals to multinodular goiters. The proposed mechanism leading to goiter formation is that the redox stress experienced when the thyroid produces hormones selects for loss of heterozygosity of KEAP1, leading to the goiters.[13]

As a drug target

[edit]

Because Nrf2 activation leads to a coordinated antioxidant and anti-inflammatory response, and Keap1 represses Nrf2 activation, Keap1 has become a very attractive drug target.[14][15][16][17]

A series of synthetic oleane triterpenoid compounds, known as antioxidant inflammation modulators (AIMs), are being developed by Reata Pharmaceuticals, Inc. and are potent inducers of the Keap1-Nrf2 pathway, blocking Keap1-dependent Nrf2 ubiquitination and leading to the stabilization and nuclear translocation of Nrf2 and subsequent induction of Nrf2 target genes.[citation needed] The lead compound in this series, bardoxolone methyl (also known as CDDO-Me or RTA 402), was in late-stage clinical trials for the treatment of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus and showed an ability to improve markers of renal function in these patients.[citation needed] However, the Phase 3 trial was halted due to safety concerns.

[edit]

References

[edit]
  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000079999 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000003308 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ "Entrez Gene: KEAP1 kelch-like ECH-associated protein 1".
  6. 1 2 Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA (October 2003). "Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival". Molecular and Cellular Biology. 23 (20): 7198–7209. doi:10.1128/mcb.23.20.7198-7209.2003. PMC 230321. PMID 14517290.
  7. 1 2 Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. (September 2008). "Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy". Proceedings of the National Academy of Sciences of the United States of America. 105 (36): 13568–13573. Bibcode:2008PNAS..10513568S. doi:10.1073/pnas.0806268105. PMC 2533230. PMID 18757741.
  8. 1 2 Wang XJ, Sun Z, Chen W, Li Y, Villeneuve NF, Zhang DD (August 2008). "Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction". Toxicology and Applied Pharmacology. 230 (3): 383–389. doi:10.1016/j.taap.2008.03.003. PMC 2610481. PMID 18417180.
  9. ↑ Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. (July 2019). "Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1". Cell. 178 (2): 316–329.e18. doi:10.1016/j.cell.2019.06.003. PMC 6625921. PMID 31257023.
  10. ↑ Lee OH, Jain AK, Papusha V, Jaiswal AK (December 2007). "An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance". The Journal of Biological Chemistry. 282 (50): 36412–36420. doi:10.1074/jbc.M706517200. PMID 17925401.
  11. ↑ Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, et al. (August 2012). "Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha". Nucleic Acids Research. 40 (15): 7416–7429. doi:10.1093/nar/gks409. PMC 3424561. PMID 22581777.
  12. ↑ Tian Y, Liu Q, Yu S, Chu Q, Chen Y, Wu K, et al. (October 2020). "NRF2-Driven KEAP1 Transcription in Human Lung Cancer". Molecular Cancer Research. 18 (10): 1465–1476. doi:10.1158/1541-7786.MCR-20-0108. PMID 32571982. S2CID 219989242.
  13. 1 2 3 Wu WL, Papagiannakopoulos T (2020-03-09). "The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer". Annual Review of Cancer Biology. 4 (1): 413–435. doi:10.1146/annurev-cancerbio-030518-055627. ISSN 2472-3428.
  14. ↑ Abed DA, Goldstein M, Albanyan H, Jin H, Hu L (July 2015). "Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents". Acta Pharmaceutica Sinica. B. 5 (4): 285–299. doi:10.1016/j.apsb.2015.05.008. PMC 4629420. PMID 26579458.
  15. ↑ Lu MC, Ji JA, Jiang ZY, You QD (September 2016). "The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update". Medicinal Research Reviews. 36 (5): 924–963. doi:10.1002/med.21396. PMID 27192495. S2CID 30047975.
  16. ↑ Deshmukh P, Unni S, Krishnappa G, Padmanabhan B (February 2017). "The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases". Biophysical Reviews. 9 (1): 41–56. doi:10.1007/s12551-016-0244-4. PMC 5425799. PMID 28510041.
  17. ↑ Kerr F, Sofola-Adesakin O, Ivanov DK, Gatliff J, Gomez Perez-Nievas B, Bertrand HC, et al. (March 2017). "Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease". PLoS Genetics. 13 (3) e1006593. doi:10.1371/journal.pgen.1006593. PMC 5333801. PMID 28253260.

Further reading

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=KEAP1&oldid=1360013908"